1. Home
  2. RAND vs RFL Comparison

RAND vs RFL Comparison

Compare RAND & RFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Rand Capital Corporation

RAND

Rand Capital Corporation

HOLD

Current Price

$11.57

Market Cap

32.4M

Sector

Finance

ML Signal

HOLD

Logo Rafael Holdings Inc. Class B

RFL

Rafael Holdings Inc. Class B

HOLD

Current Price

$1.31

Market Cap

61.1M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
RAND
RFL
Founded
1969
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Real Estate
Sector
Finance
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
32.4M
61.1M
IPO Year
1996
2017

Fundamental Metrics

Financial Performance
Metric
RAND
RFL
Price
$11.57
$1.31
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
4.2K
103.5K
Earning Date
06-01-2026
03-30-2026
Dividend Yield
10.21%
N/A
EPS Growth
N/A
28.28
EPS
N/A
N/A
Revenue
N/A
$917,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
43.96
52 Week Low
$10.05
$1.12
52 Week High
$21.30
$3.19

Technical Indicators

Market Signals
Indicator
RAND
RFL
Relative Strength Index (RSI) 50.07 52.39
Support Level $10.31 $1.35
Resistance Level $12.50 $1.38
Average True Range (ATR) 0.49 0.12
MACD -0.00 -0.01
Stochastic Oscillator 36.61 32.73

Price Performance

Historical Comparison
RAND
RFL

About RAND Rand Capital Corporation

Rand Capital Corp is a closed-end, externally managed, non-diversified investment company. The company's investment objective is to generate current income and, when possible, complement its current income with capital appreciation by focusing its debt and related equity investments in privately-held, lower middle market companies with committed and experienced managements in a broad variety of industries. It predominantly invests in higher-yielding debt instruments.

About RFL Rafael Holdings Inc. Class B

Rafael Holdings Inc is a biotechnology firm that develops pharmaceuticals and invests in clinical and early-stage companies in pharmaceuticals and medical devices. Trappsol Cyclo is in Phase 3 trials for Niemann-Pick Disease Type C1. The company focuses on completing these trials, seeking regulatory approval, and commercializing the product. It also invests in portfolio companies including Cyclo, LipoMedix, Barer, Rafael Medical Devices, Cornerstone, and Day Three, targeting therapeutics for unmet medical needs. The business operates through three segments: Healthcare, Infusion Technology, and Real Estate. Operations are based in the United States and Israel.

Share on Social Networks: